Clinical Evaluation of the Novel Rapid Nucleic Acid Amplification Point-of-Care Test (Smart Gene SARS-CoV-2) in the analysis of Nasopharyngeal and Anterior Nasal samples - Kiyasu, Yoshihiko; Owaku, Masato; Akashi, Yusaku; Takeuchi, Yuto; Narahara, Kenji; Mori, Sunao; Nagano, Takashi; Notake, Shigeyuki; Ueda, Atsuo; Nakamura, Koji; Ishikawa, Hiroichi; Suzuki, Hiromichi (medRxiv, 2021)
Introduction Smart Gene is a point-of-care (POC)-type automated molecular testing platform that can be performed with 1 minute of hands-on-time. Smart Gene SARS-CoV-2 is a newly developed Smart Gene molecular assay for the detection of SARS-CoV-2. The analytical and clinical performance of Smart Gene SARS-CoV-2 has not been evaluated.Methods Nasopharyngeal and anterior nasal samples were prospectively collected from subjects referred to the local PCR center from March 25 to July 5, 2021. Two swabs were simultaneously obtained for the Smart Gene SARS-CoV-2 assay and the reference real-time RT-PCR assay, and the results of Smart Gene SARS-CoV-2 were compared to the reference real-time RT-PCR assay.Results Among a total of 1150 samples, 68 of 791 nasopharyngeal samples and 51 of 359 anterior nasal samples were positive for SARS-CoV-2 in the reference real-time RT-PCR assay. In the testing of nasopharyngeal samples, Smart Gene SARS-CoV-2 showed the total, positive and negative concordance of 99.2% (95% confidence interval [CI]: 98.4–99.7%), 94.1% (95% CI: 85.6–98.4%) and 99.7% (95% CI: 99.0–100%), respectively. For anterior nasal samples, Smart Gene SARS-CoV-2 showed the total, positive and negative concordance of 98.9% (95% CI: 97.2–99.7%), 98.0% (95% CI: 89.6–100%) and 99.0% (95% CI: 97.2–99.8%), respectively. In total, 5 samples were positive in the reference real-time RT-PCR and negative in Smart Gene SARS-CoV-2, whereas 5 samples were negative in the reference real-time RT-PCR and positive in Smart Gene SARS-CoV-2.Conclusion Smart Gene SARS-CoV-2 showed sufficient analytical performance for the detection of SARS-CoV-2 in nasopharyngeal and anterior nasal samples.Competing Interest StatementMizuho Medy provided fees for research expenses and provided Smart Gene SARS–CoV–2 free of charge. Masato Owaku, Kenji Narahara, Sunao Mori, Takashi Nagano are employed by Mizuho Medy, the developer of Smart Gene SARS–CoV–2. Hiromichi Suzuki received a consultation fee from Mizuho MedyFunding StatementMizuho Medy provided fees for research expenses and provided Smart Gene SARS-CoV-2 free of charge. Masato Owaku, Kenji Narahara, Sunao Mori, Takashi Nagano are employed by Mizuho Medy, the developer of Smart Gene SARS-CoV-2. Hiromichi Suzuki received a consultation fee from Mizuho Medy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects provided their consent for enrollment. If multiple samples were collected from the same subject, they were all treated as individual samples. The ethics committee of TMCH approved the present study (approval number: 2021-008).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome restrictions will apply.